7:30am - 8:00am Registration and Breakfast
8:00am - 8:05am Welcome and Opening Remarks
o Sadhana Jackson, MD, Tenure-track Investigator, Head of Developmental Therapeutics, NCI, Pediatric Oncology Branch and NINDS, Surgical Neurology Branch, NIH
o Maria Castro, PhD, Professor of Neurosurgery and Cell and Developmental Biology, University of Michigan
8:05am - 9:05am Overview of G34R/V Glioma
o Epidemiology of Gliomas in AYA population
Quinn Ostrom, PhD, Assistant Professor, Neurosurgery, Population Health Sciences, Duke University, School of Medicine
o Neuropathology: An Update for the Clinician
Patrick J Cimino, MD, Staff Clinician
Surgical Neurology Branch, NINDS, NIH
o Neuroimaging features of G34R/V mutated gliomas
Sohil Patel, MD, Associate Professor, Radiology and Medical Imaging Department, University of Virginia Health
o Panel Question and Answers
Moderated by Sadhana Jackson
9:05am - 10:40am
Surgical Management and Genomics of G34R/V Diffuse Gliomas
o Historical lens of Diffuse Gliomas
Suzanne Baker, MD, Endowed Chair in Brain Tumor Resarch, Developmental Neurobiology, St. Jude Childern's Research Hospital
o Surgical Challenges and Precision Therapy for Cortical Gliomas
Chetan Bettagowda, MD, PhD, Professor, Director, Reza Khatib Brain Tumor Center, Johns Hopkins Hospital
o Methylation of Glioma
Houtan Noushmehr, PhD, Associate Professor of (epi)Genomics and Bioinformatics, Henry Ford Health System
o Neuro-glial cellular architecture driven by G34R mutation
Mario Suva, MD, PhD, Associate Professor of Pathology, Harvard Medical School and Massachusetts General Hospital, Dana-Farber/Harvard Cancer Center
o Computational Genomics
Claudia Kleinman, Associate Member, Assistant Professor, McGill Centre for Translational Research in Cancer, Lady Davis Institute for Medical Research, McGill University
o Panel Question and Answers
Moderated by Suzanne Baker
10:40am - 10:55am Break and Poster Exhibition
10:55am - 12:15pm Translational Research
o Characterization of the Immune Microenvironment
Maria Castro, PhD, Professor of Neurosurgery and Cell and Developmental Biology, University of Michigan
o Implementation of Immune mediated Gene therapeutics in H3.3G34R mutated high grade gliomas
Pedro Lowenstein, Professor of Neurosurgery, Professor, Cell and Developmental Biology, University of Michigan
o Base excision repair: A promising therapeutic target in H3G34 mutant diffuse hemispheric glioma
Laura Canty, PhD, Research Project Coordinator, University of Toronto, The Hospital for Sick Kids
o Gabaergic neuronal lineage development determines clinically actionable targets in diffuse hemispheric glioma, H3G34-mutant Gustavo A.V. Cruzeiro, Postdoctoral Fellow, Dana-Farber Cancer Institute
o Panel Question and Answers
Moderated by Sadhana Jackson
12:00am - 1:00pm Lunch and Poster Session
1:00pm ¿ 2:05pm Small Group Discussions -clinicians/scientists mixed in each group
o Identifying and Addressing Gaps in Diagnosis, Clinical Care and Research (written answers)
Leads: Nellan, Castro, Becher
o Sharing (presentation of each small group with discussion)
2:05pm - 3:40pm
Management of G34R/V Gliomas: What Trials and Research are on the Horizon?
o Overview of NCI/NINDS Sponsored Clinical Trials
Sadhana Jackson, MD, Tenure-track Investigator, Head of Developmental Therapeutics, NCI, Pediatric Oncology Branch and NINDS, Surgical Neurology Branch, NIH
o G34R/V therapeutic targeted clinical trial
Tom Davidson, MD, Associate Professor of Pediatrics, Children's Hospital of Los Angeles, Keck School of Medicine of USC
o Tumor Genomics: What Every Clinician Needs to Know
Adam Resnick, PhD, Co-Director of Data Driven Discovery in Biomedicine and Scientific Chair for Children¿s Brain Tumor Network and Pacific Pediatric Neuro-Oncology Consortium
o Chemokines in myeloid-tumor cell crosstalk in pediatric high-grade gliomas
Delores Hambardzumyan, PhD, MBA, Professor of Oncological Sciences and Neurosurgery, Mount Sinai. o G34R/V therapy: Learning from other pHGG trials and subtypes
Adam Green, Associate Professor, Pediatrics-Heme/Onc and Bone Marrow Transplantation, University of Colorado Anschutz School of Medicine
o Biotherapeutic delivery for brain cancer: Landscape and new approaches to cross the blood-brain barrier
Robert Thorne, PhD, Denali Fellow, Denali Therapeutics
o What can be learned with high throughput drug screening for H3.3 K27? Kelli Wilson, PhD, Acting Director of Compound Management, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, NIH
o Panel Question and Answers
Moderated by Maria Castro
3:40pm -4:00pm Break | Poster Exhibition-Meet the Experts
4:00pm - 4:50pm Tumor Board Cases
o G34R Tumor Board Case: Management recurrent disease | | Case Presenter, Brett Theeler, MD
Panel
o Pathologist: Jason Gregory, MD
o Radiation Oncologist: Peter Mathen
o Neurosurgeon: Karin Muraszko
o Radiologist: Nadia Biassou, MD
o G34R Tumor Board Case: Management recurrent disease | | Case Presenter, Oren Becher, MD
Panel
o Pathologist: Patrick J Cimino
o Radiation Oncologist: Peter Mathen
o Neurosurgeon: Karin Muraszko
o Radiologist: Nadia Biassou, MD
o G34R Tumor Board Case: Management recurrent disease | | Case Presenter, Sheila McThenia, MD
Panel
o Pathologist: Dr. Patrick J Cimino
o Radiation Oncologist: Peter Mathen
o Neurosurgeon: Karin Muraszko
o Radiologist: Nadia Biassou
4:50pm - 5:00pm
Closing Remarks
Sadhana Jackson, MD and Maria Castro, PhD
(U.S. Department of Health and Human Services)